Sarah Gheuens Sells 4,091 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 4,091 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $34.17, for a total transaction of $139,789.47. Following the sale, the insider directly owned 61,271 shares of the company's stock, valued at approximately $2,093,630.07. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sarah Gheuens also recently made the following trade(s):

• On Tuesday, June 24th, Sarah Gheuens sold 2,909 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $33.54, for a total transaction of $97,567.86.

Agios Pharmaceuticals Stock Up 2.0%

AGIO traded up $0.71 during trading on Friday, reaching $36.06. The company had a trading volume of 258,713 shares, compared to its average volume of 653,612. The business has a 50 day simple moving average of $31.92 and a 200-day simple moving average of $31.93. The stock has a market cap of $2.09 billion, a P/E ratio of 3.21 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. As a group, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares during the period. Erste Asset Management GmbH raised its stake in shares of Agios Pharmaceuticals by 10.9% during the first quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after acquiring an additional 220,000 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $49,290,000. Frazier Life Sciences Management L.P. grew its stake in Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after purchasing an additional 25,600 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after purchasing an additional 265,637 shares during the period.

Wall Street Analysts Forecast Growth

AGIO has been the subject of a number of research reports. Scotiabank dropped their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $58.60.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.